Glofitamab toont activiteit bij recidief of refractair B-cel-lymfoom, retrospectieve single-center analyse

This single-center retrospective analysis enrolled 32 patients with relapsed/refractory (R/R) B-cell lymphoma who received glofitamab-containing regimens at Beijing Tongren Hospital. Study endpoints were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and safety. Univariate and multivariate Cox regression analyses were conducted to identify prognostic factors. The median follow-up duration was 414 (95% CI: 175 - not reached) days, with a 180-day PFS rate of 39.1% (95% CI: 24.0%-63.7%) and a 180-day OS rate of 72.2% (95% CI: 57.5%-90.8%). The ORR was 47.6% and the complete response rate (CRR) was 14.3% in 21 evaluable patients among 25 patients who received glofitamab as salvage therapy. All 6 patients who received glofitamab as bridging therapy achieved a partial response. Univariate analysis revealed the number of prior treatment lines (HR=1.55, 95% CI: 1.15-2.07, P=0.004), prior CAR-T cell therapy (HR=3.35, 95% CI: 1.07-10.49, P=0.038), prior treatment with bendamustine (HR=3.45, 95% CI: 1.05-11.41, P=0.042), and glofitamab monotherapy (HR=4.18, 95% CI: 1.42-12.33, P=0.010) as risk factors for PFS. The incidence of cytokine release syndrome (CRS) was 28.1%, with one patient also developing immune effector cell-associated neurotoxicity syndrome (ICANS), and no grade of ≥3 CRS or ICANS was observed. Glofitamab demonstrates considerable potential in R/R B-cell lymphoma; however, its efficacy as monotherapy is limited in heavily pretreated patients. Combination regimens may better address clinical needs; however, enhanced monitoring for adverse events and supportive care are warranted.